ELMO CPAP: an innovative type of ventilatory support for COVID-19-related acute respiratory distress syndrome
Authors:
- Andrea Mazza BelieroABAndrea Mazza Beliero
- Ana Paula Pires LazaroALAna Paula Pires Lazaro
- Marza de Sousa ZaranzaMZMarza de Sousa Zaranza
- Giovanna Mazza Cruz LimaGLGiovanna Mazza Cruz Lima
- Alvaro Rolim GuimaraesAGAlvaro Rolim Guimaraes
- Nilcyeli Linhares AragaoNANilcyeli Linhares Aragao
- Gdayllon Cavalcante MenesesGMGdayllon Cavalcante Meneses
- Marcelo Alcantara HolandaMHMarcelo Alcantara Holanda
- Polianna Lemos Moura Moreira AlbuquerquePAPolianna Lemos Moura Moreira Albuquerque
- Geraldo Bezerra da Silva JuniorGJGeraldo Bezerra da Silva Junior
- Paula Frassinetti Castelo Branco Camurca FernandesPFPaula Frassinetti Castelo Branco Camurca Fernandes
Open Access
- 26 December 2023
- journal article
- research article
- Published by Sociedade Brasileira de Pneumologia e Tisiologia in Jornal Brasileiro de Pneumologia
- Vol. 49 (6) , e20230227
Abstract
Objective: To assess whether the use of ELMO, a helmet for noninvasive ventilation created in Brazil, had a positive impact on the prognosis of patients with hypoxemic respiratory failure caused by severe COVID-19. Methods: This is a retrospective study of 50 critically ill COVID-19 patients. Epidemiological, clinical, and laboratory data were collected on ICU admission, as well as before, during, and after ELMO use. Patients were divided into two groups (success and failure) according to the outcome. Results: ELMO use improved oxygenation parameters such as Pao(2), Fio(2), and the Pao(2)/Fio(2) ratio, and this contributed to a gradual reduction in Fio 2, without an increase in CO2, as determined by arterial blood gas analysis. Patients in the success group had significantly longer survival (p < 0.001), as determined by the Kaplan-Meier analysis, less need for intubation (p < 0.001), fewer days of hospitalization, and a lower incidence of acute kidney injury in comparison with those in the failure group. Conclusions: The significant improvement in oxygenation parameters, the longer survival, as reflected by the reduced need for intubation and by the mortality rate, and the absence of acute kidney injury suggest that the ELMO CPAP system is a promising tool for treating ARDS and similar clinical conditions.Keywords
This publication has 25 references indexed in Scilit:
- Characterisation of the first 250 000 hospital admissions for COVID-19 in Brazil: a retrospective analysis of nationwide dataThe Lancet Respiratory Medicine, 2021
- Helmet CPAP to treat hypoxic pneumonia outside the ICU: an observational study during the COVID-19 outbreakResearch Square, 2021
- Identification of pathophysiological patterns for triage and respiratory support in COVID-19The Lancet Respiratory Medicine, 2020
- COVID-19 cytokine storm: the interplay between inflammation and coagulationThe Lancet Respiratory Medicine, 2020
- The pathogenesis and treatment of the `Cytokine Storm' in COVID-19Journal of Infection, 2020
- Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area (vol 323, pg 2050, 2020)2020
- Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City AreaJAMA, 2020
- Acute Kidney Injury by SARS-CoV-2 virus in patients with COVID-19: an integrative reviewRevista Brasileira de Enfermagem, 2020
- Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1)Critical Care, 2013
- Helmet Continuous Positive Airway Pressure vs Oxygen Therapy To Improve Oxygenation in Community-Acquired PneumoniaChest, 2010